Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2009

View Archived Issues

Antihypertensive agent candesartan shows clinical promise for prevention of cognitive decline

Mimopezil SR implants are well-tolerated with comparable efficacy to donepezil in AD

Vertex claims ABC and CFTR modulators for the treatment of cystic fibrosis

Bayer Schering Pharma developing Toll-like receptor modulators as anti-inflammatory agents

Bayer Schering Pharma describes new progesterone receptor antagonists for gynecological disorders

NeuroSearch prepares and tests novel nicotinic alpha7 receptor agonists

Merz launches Xeomin in Canada for several neuromuscular conditions

QRxPharma initiates phase II proof-of-concept study for MoxDuo in pain

MJFF awards grant to Targacept to fund research into levodopa-induced dyskinesias

Hisamitsu initiates cash tender offer for all outstanding shares of Noven common stock

CHMP issues positive opinion for Regeneron's rilonacept for CAPS

PolyMedix and UMass receive military funding to develop defensin mimetics

FDA approves Aradigm's IND for phase IIb study of inhaled liposomal ciprofloxacin in BE

Merck Serono considers appealing CHMP negative opinion on Erbitux for NSCLC

CHMP issues positive opinion on Keppra in children with partial-onset epilepsy

Genmab completes recruitment in phase II Arzerra study in relapsed DLBCL

Tamibarotene receives positive opinion for orphan medicinal product status

Orexo reports phase III results for KW-2246 in Japan

NeurogesX reports preliminary results of FDA-requested Qutenza study

Ambrilia terminates phase III clinical study of octreotide in patients with acromegaly

Alizyme suspends trading in ordinary shares and will be placed in administration

Seattle Genetics commences phase II brentuximab vedotin retreatment trial

Raltegravir shows comparable antiretroviral activity to efavirenz in HIV-1; phase II data disclosed

The HNE inhibitor POL-6014 shows potential in mouse model of acute lung injury

Anti-inflammatory agent bindarit reduces MCP-1 excretion in patients with active lupus nephritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...